PMC:7605643 / 36416-36540 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T189","span":{"begin":96,"end":104},"obj":"Body_part"}],"attributes":[{"id":"A189","pred":"fma_id","subj":"T189","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"In diseases, the IL-6 inhibitory strategy begins with the development of the anti-IL-6 receptor antibody, tocilizumab (TCZ)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T350","span":{"begin":17,"end":19},"obj":"Chemical"},{"id":"T352","span":{"begin":82,"end":84},"obj":"Chemical"},{"id":"T354","span":{"begin":106,"end":117},"obj":"Chemical"}],"attributes":[{"id":"A350","pred":"chebi_id","subj":"T350","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A351","pred":"chebi_id","subj":"T350","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A352","pred":"chebi_id","subj":"T352","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A353","pred":"chebi_id","subj":"T352","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A354","pred":"chebi_id","subj":"T354","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"}],"text":"In diseases, the IL-6 inhibitory strategy begins with the development of the anti-IL-6 receptor antibody, tocilizumab (TCZ)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T207","span":{"begin":0,"end":124},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In diseases, the IL-6 inhibitory strategy begins with the development of the anti-IL-6 receptor antibody, tocilizumab (TCZ)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"840","span":{"begin":17,"end":21},"obj":"Gene"},{"id":"841","span":{"begin":82,"end":86},"obj":"Gene"},{"id":"868","span":{"begin":106,"end":117},"obj":"Chemical"},{"id":"869","span":{"begin":119,"end":122},"obj":"Chemical"}],"attributes":[{"id":"A840","pred":"tao:has_database_id","subj":"840","obj":"Gene:3569"},{"id":"A841","pred":"tao:has_database_id","subj":"841","obj":"Gene:3569"},{"id":"A868","pred":"tao:has_database_id","subj":"868","obj":"MESH:C502936"},{"id":"A869","pred":"tao:has_database_id","subj":"869","obj":"MESH:C502936"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In diseases, the IL-6 inhibitory strategy begins with the development of the anti-IL-6 receptor antibody, tocilizumab (TCZ)."}